carbenoxolone sodium has been researched along with ALS - Amyotrophic Lateral Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, Y; Jin, S; Kawanokuchi, J; Li, E; Li, H; Liang, J; Mizoguchi, H; Mizuno, T; Mori, R; Noda, M; Parajuli, B; Sato, J; Sobue, G; Sonobe, Y; Suzumura, A; Takeuchi, H; Yamanaka, K; Yasuoka, S; Zhou, Y | 1 |
| Suzumura, A | 1 |
2 other study(ies) available for carbenoxolone sodium and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Behavior, Animal; Carbenoxolone; Disease Progression; Female; Gap Junctions; Glycyrrhetinic Acid; Humans; Ion Channels; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Spinal Cord; Superoxide Dismutase | 2011 |
[Microglia and neuronal degeneration].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Carbenoxolone; Cytokines; Disease Models, Animal; Drug Design; Glutamates; Humans; Microglia; Molecular Targeted Therapy; Multiple Sclerosis; Nerve Degeneration; Neurogenic Inflammation | 2010 |